Impact of SARS-CoV-2 infective exacerbation of chronic obstructive pulmonary disease on clinical outcomes in a prospective cohort study of hospitalised adults
Journal of the Royal Society of Medicine · 2023-11 · 116 (11) · 371-385
DOI: 10.1177/01410768231184162 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of the Royal Society of Medicine, online erschienen am 05.07.2023. Verfasst von Catherine Hyams und 20 weiteren Autor:innen. Beteiligte Einrichtung: Academic Respiratory Unit and Bristol Vaccine Centre, University of Bristol, Bristol, BS15, UK. Hauptthemen laut MEDLINE: COVID-19, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Pfizer Inc.
Themen: COPD
Abstract (Originalsprache)
Objectives
To determine whether acute exacerbations of chronic obstructive pulmonary disease (AECOPD) triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have worse outcomes than AECOPD caused by other infectious agents or non-infective AECOPD (NI-COPD).
Design
A two-hospital prospective cohort study of adults hospitalised with acute respiratory disease. We compared outcomes with AECOPD and a positive test for SARS-CoV-2 (n = 816), AECOPD triggered by other infections (n = 3038) and NI-COPD (n = 994). We used multivariable modelling to adjust for potential confounders and assessed variation by seasons associated with different SARS-CoV-2 variants.
Setting
Bristol UK, August 2020–May 2022.
Participants
Adults (≥18 y) hospitalised with AECOPD. Main outcome measures We determined the risk of positive pressure support, longer hospital admission and mortality following hospitalisation with AECOPD due to non-SARS-CoV-2 infection compared with SARS-CoV-2 AECOPD and NI-COPD.
Results
Patients with SARS-CoV-2 AECOPD, in comparison to non-SARS-CoV-2 infective AECOPD or NI-COPD, more frequently required positive pressure support (18.5% and 7.5% vs. 11.7%, respectively), longer hospital stays (median [interquartile range, IQR]: 7 [3–15] and 5 [2–10] vs. 4 [2–9] days, respectively) and had higher 30-day mortality (16.9% and 11.1% vs. 5.9%, respectively) (all p < 0.001). In adjusted analyses, SARS-CoV-2 AECOPD was associated with a 55% (95% confidence interval [95% CI]: 24–93), 26% (95% CI: 15–37) and 35% (95% CI: 10–65) increase in the risk of positive pressure support, hospitalisation length and 30-day mortality, respectively, relative to non-SARS-CoV-2 infective AECOPD. The difference in risk remained similar during periods of wild-type, Alpha and Delta SARS-CoV-2 strain dominance, but diminished during Omicron dominance.
Conclusions
SARS-CoV-2-related AECOPD had worse patient outcomes compared with non-SARS-CoV-2 AECOPD or NI-AECOPD, although the difference in risks was less pronounced during Omicron dominance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Academic Respiratory Unit and Bristol Vaccine Centre, University of Bristol, Bristol, BS15, UK.
- Engineering Mathematics, University of Bristol, Bristol, Bristol, BS8, UK.
- Academic Respiratory Unit, University of Bristol, Southmead Hospital, Bristol, Bristol, BS15, UK.
- Vaccines Medical Development, Scientific and Clinical Affairs, Pfizer Inc., Collegeville, PA 19426, USA.
- Clinical Research and Imaging Centre, UHBW NHS Trust, Bristol, Bristol, BS2, UK.
- Academic Respiratory Unit, Southmead Hospital, Bristol, Bristol, BS15, UK.
ORCID-Profile: Catherine Hyams
Förderung
- Medical Research Council
- Pfizer Inc
Zitieren
APA
Hyams, C., Qian, G., Nava, G., Challen, R., Begier, E., Southern, J., Lahuerta, M., Nguyen, J. L., King, J., Morley, A., Clout, M., Maskell, N., Jodar, L., Oliver, J., Ellsbury, G., McLaughlin, J. M., Gessner, B. D., Finn, A., Danon, L., …, & Avon CAP Research Group (2023). Impact of SARS-CoV-2 infective exacerbation of chronic obstructive pulmonary disease on clinical outcomes in a prospective cohort study of hospitalised adults. Journal of the Royal Society of Medicine, 116(11), 371-385. https://doi.org/10.1177/01410768231184162
Vancouver
Hyams C, Qian G, Nava G, Challen R, Begier E, Southern J, et al. Impact of SARS-CoV-2 infective exacerbation of chronic obstructive pulmonary disease on clinical outcomes in a prospective cohort study of hospitalised adults. Journal of the Royal Society of Medicine. 2023;116(11):371-385. doi:10.1177/01410768231184162
BibTeX
@article{Hyams2023,
author = {Hyams, Catherine and Qian, George and Nava, George and Challen, Robert and Begier, Elizabeth and Southern, Jo and Lahuerta, Maria and Nguyen, Jennifer L and King, Jade and Morley, Anna and Clout, Madeleine and Maskell, Nick and Jodar, Luis and Oliver, Jennifer and Ellsbury, Gillian and McLaughlin, John M and Gessner, Bradford D and Finn, Adam and Danon, Leon and Dodd, James W and Avon CAP Research Group, Avon CAP Research Group},
title = {Impact of SARS-CoV-2 infective exacerbation of chronic obstructive pulmonary disease on clinical outcomes in a prospective cohort study of hospitalised adults},
journal = {Journal of the Royal Society of Medicine},
year = {2023},
volume = {116},
number = {11},
pages = {371--385},
doi = {10.1177/01410768231184162}
}
EUVIMED